An interventional study of Nutrition education and Supplement in Down Syndrome (DS) and Supplementation, sponsored by Universidad de Burgos. Completed at 1 site in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-30.
Sponsored by Universidad de Burgos · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies in Down Syndrome with a site in Spain — 9 open to participants now, 9 under way, 1 of them phase 3. Down Syndrome · Spain.
Among the 36 studies in Down Syndrome with a site in Spain, this one is the 13th largest by enrollment of the 18 interventional ones that give a count, is one of 4 that started in 2025, is one of 10 with no phase, and was the 32nd registered.
439 studies on the registry are indexed under Down Syndrome; 99 are open to participants now.
Browse Down Syndrome studies →9 of the 36 studies in Down Syndrome with a site in Spain are open now. Recruiting first, the newest first:
Alnylam Pharmaceuticals · Sites in Spain, United States, United Kingdom
Ages 40–55
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau · Sites in Spain
Ages 40+
Aelis Farma · Sites in Spain, France, Italy
Ages 16–32
University of Seville · Sites in Spain
Ages 1 mo–18 mo
University of Seville · Sites in Spain
Ages 4–30
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 74 Down Syndrome studies recruiting now, 14 (19%) set no upper age limit and 57 (77%) stop at 75 or younger; 60 take children under 18; 19 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 6 · Phase 3 1
First in 2009; this study’s year is marked. 4 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 32 is below the median of 38 across 287 interventional studies indexed under Down Syndrome.
Median enrollment 58 across the 18 interventional studies, 113 across the 18 observational. Of the 20 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 36 have an industry lead sponsor. The 10 most frequent:
Universidad de Burgos is the lead sponsor of 25 studies on the registry; 4 are open to participants now.
Universidad de Burgos has 1 study filed under Down Syndrome — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 36 studies in Down Syndrome with a site in Spain, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Purpose:
This study will test whether 8 weeks of creatine and HMB supplementation can improve muscle strength, body composition, balance, and overall health in people with Down syndrome. Participants will also receive nutrition tips during the study.
Who can participate:
People with Down syndrome who can perform basic physical tasks. Must provide consent from the participant and legal guardian.
What participants will do:
Take creatine (3 g/day) and HMB (3 g/day) or placebo for 8 weeks. Complete tests for muscle strength, balance, and cognitive function. Undergo body composition scans and give blood samples for health markers.
Timing:
All tests and blood samples are taken before and after each 8-week period.
Importance:
Results will help determine if creatine and HMB can safely improve strength, balance, and overall health in people with Down syndrome.
This study is an 8-week randomized, placebo-controlled, crossover trial designed to evaluate the effects of daily supplementation with creatine monohydrate (3 g) and beta-hydroxy-beta-methylbutyrate (HMB, 3 g) on body composition, muscle strength, balance, cognitive function, and biomarkers of oxidative stress and inflammation in individuals with Down syndrome. Participants will receive nutritional education throughout the intervention to support a balanced diet.
Primary outcomes include lean mass measured by dual-energy X-ray absorptiometry (DXA).
Secondary outcomes include fat-free mass (bioimpedance), bone mineral density (DXA), handgrip strength, lower limb strength (Five Times Sit-to-Stand Test), upper and lower body isometric strength (K-Pull test), balance (4-Stage Balance Test), and cognitive function assessed by the Timed Up and Go Dual Task. Blood biomarkers of oxidative stress and inflammation, including reduced glutathione (GSH), superoxide dismutase (SOD), C-reactive protein (CRP), interleukins (IL-1, IL-6, IL-7), and tumor necrosis factor-alpha (TNF-α), will be assessed before and after each supplementation period.
All assessments will be performed at baseline and at the end of each 8-week supplementation phase, allowing for evaluation of both physiological and functional responses to creatine and HMB supplementation in this population.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive placebo supplementation
Other: Nutrition education · Dietary Supplement: Placebo
Participants will receive creatine monohydrate and beta-hydroxy-beta-methylbutyrate supplementation
Other: Nutrition education · Dietary Supplement: Supplement
Participants and their families will also take part in nutrition education sessions to promote healthy eating and lifestyle habits.
Supplementation with 3 g/day of creatine monohydrate abd 3 g/day of beta-hydroxy-beta-methylbutyrate for 8 weeks
Supplementation with 6 g/day of inulin orally for 8 weeks
Lean mass
Lean mass (kg) will be evaluated using dual-energy X-ray absorptiometry (DXA): GE Lunar Prodigy DXA device (GE Healthcare, Madison, WI, USA; Encore software version).
Time frame: Baseline (within 2 days before starting supplementation) and at 8 weeks (end of supplementation)
Handgrip strength
Handgrip strength (kg) will be assessed using a handgrip dynamometer.
Time frame: Baseline (within 2 days before starting supplementation) and at 8 weeks (end of supplementation)
Bone mineral density
Total bone mineral density (g/cm2) will be evaluated using dual-energy X-ray absorptiometry (DXA): GE Lunar Prodigy DXA device (GE Healthcare, Madison, WI, USA; Encore software version).
Time frame: Baseline (within 2 days before starting supplementation) and at 8 weeks (end of supplementation)
Reduced glutathione (GSH).
Blood samples will be collected to assess levels of reduced glutathione (GSH).
Time frame: Baseline (within 2 days before starting supplementation) and at 8 weeks (end of supplementation)
C-reactive protein (CRP)
Blood samples will be collected to assess levels of inflammation including C-reactive protein (CRP).
Time frame: Baseline (within 2 days before starting supplementation) and at 8 weeks (end of supplementation)
Superoxide dismutase (SOD) activity.
Blood samples will be collected to assess levels of superoxide dismutase (SOD) activity.
Time frame: Baseline (within 2 days before starting supplementation) and at 8 weeks (end of supplementation)
Blood levels of interleukins (IL-1, IL-6, IL-7).
Blood samples will be collected to assess levels of interleukins (IL-1, IL-6, IL-7).
Time frame: Baseline (within 2 days before starting supplementation) and at 8 weeks (end of supplementation)
Tumor necrosis factor-alpha (TNF-α).
Blood samples will be collected to assess levels of tumor necrosis factor-alpha (TNF-α).
Time frame: Baseline (within 2 days before starting supplementation) and at 8 weeks (end of supplementation)
Fat-free mass
Fat free mass (kg) will be analysed using bioimpedance: InBody S10.
Time frame: Baseline (within 2 days before starting supplementation) and at 8 weeks (end of supplementation)
Lower limb strength
Lower limb strength will be assessed using the Five Times Sit-to-Stand Test (5xSTS), which involved recording the time taken to rise from a 45 cm highchair five times as quickly as possible without using the arms for support.
Time frame: Baseline (within 2 days before starting supplementation) and at 8 weeks (end of supplementation)
Balance
Balance will be using the 4-Stage Balance Test. It involves holding four progressively difficult positions for at least 10 seconds each: Feet together: 1 point if the position is held for 10 seconds or more. Partial semi-tandem: 1 point if the position is held for 10 seconds or more. Semi-tandem: * 2 points: If the position is held for more than 10 seconds. * 1 point: If the position is held for between 3 and 9.99 seconds. * 0 points: If the position is held for less than 3 seconds. The score ranges from 0 to 4 (best balance).
Time frame: Baseline (within 2 days before starting supplementation) and at 8 weeks (end of supplementation)
Cognitive function
Cognitive function will be assessed with Timed Up and Go Dual Task (TUGdt) test. The participant first performs the Timed Up and Go (TUG) test alone, standing up from a chair, walking a short distance (3 meters) turning, and sitting back down, while simultaneously naming animals within a 10-second period, which assesses verbal fluency. The time taken to complete these distances will be recorded, and the fluency in naming the animals will be assessed.
Time frame: Baseline (within 2 days before starting supplementation) and at 8 weeks (end of supplementation)
Isometric lower body strength
The K-Pull test will be used to evaluate isometric lower body strength Participants will perform a seated knee extension test, pushing their leg against the dynamometer with maximal effort. Participants will exert their maximum force against the unyielding device for 3-5 seconds. The peak force achieved (in Newtons) over a minimum of two trials will be recorded
Time frame: Baseline (within 2 days before starting supplementation) and at 8 weeks (end of supplementation)
Isometric upper body strength
The K-Pull test will be used to evaluate isometric upper body strength Participants will stand with their back against a wall to stabilize the torso. The participant will be instructed to exert a maximal force by pushing their arm outward against the device for 3-5 seconds.The peak force achieved (in Newtons or kilograms-force) over a minimum of two trials will be recorded.
Time frame: Baseline (within 2 days before starting supplementation) and at 8 weeks (end of supplementation)
Plan to share: No
No publications or documents are linked to this record.
Ran from Sep 2025 to primary completion in Apr 2026, 7 months.
Of 163 non-industry interventional studies with no phase under Down Syndrome, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 33. This study's 7 months is below that.
Counting every sponsor, half of 165 studies reached it within 11 months; a quarter within 3 and three quarters within 35.
Completion moved once since we started tracking on Sep 25, 2026: May 2026 → Apr 2026, on Oct 30, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Universidad de Burgos